Item 8.01 Other Events.
On January 8, 2020, Blueprint Medicines Corporation (the "Company") issued a
press release announcing top-line data from its Phase 1/2 ARROW clinical trial
evaluating pralsetinib for the treatment of patients with RET fusion-positive
non-small cell lung cancer ("NSCLC") and that the Company has initiated the
submission of a rolling new drug application ("NDA") to the U.S. Food and Drug
Administration for the treatment of patients with RET fusion-positive NSCLC. The
Company expects to complete the NDA submission in the first quarter of 2020. A
copy of the press release is filed herewith as Exhibit 99.1 to this Current
Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release issued by Blueprint Medicines Corporation on
January 8, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
2
© Edgar Online, source Glimpses